Shimiao Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shimiao Zhu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Yang Tang
Tianjin Institute of Urology
3 shared publicationsHui Zhang
Cangzhou Central Hospital
2 shared publicationsJianmin Wang
Tianjin Institute of Urology
2 shared publicationsPeicai Liu
The 2nd Hospital of Tianjin Medical University
2 shared publicationsGuang Sun
1 shared publicationJian-Min Wang
1 shared publication
Latest Publications
- 16 March 2012
- Published by Springer Nature in Molecular Biology Reports
- Vol. 39 (6) , 7211
Erratum to: DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case–control studies
- 16 March 2012
- Published by Springer Nature in Molecular Biology Reports
- Vol. 39 (6) , 7211
Erratum to: DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case–control studies
- 1 November 2011
- Vol. 17 (11) , 1007-10
[Stage I testis teratoma in adults: treatment options and recurrence factors].
To study the clinical outcomes of stage I testis teratoma, including pure teratoma, and to provide information on the treatment options for this disease. We retrospectively analyzed 27 cases of orchiectomy for stage I testis teratoma, excluding epidermoid cyst, and investigated its recurrence associated with treatment methods and clinicopathological factors. Four of the 27 cases relapsed, all in the orchiectomy group and confined to the retroperitoneal region, 3 with and the other 1 without risk factors, but with no death. No recurrence was found in those treated by orchiectomy followed by chemotherapy with bleomycin, etoposide and platinum (BEP). The total rate of recurrence was 15.8%. No severe side effects were observed in the 9 patients undergoing adjuvant BEP chemotherapy. Risk factors may increase the recurrence rate of stage I testis teratoma, while postoperative adjuvant chemotherapy can reduce it, including that of pure teratoma, though surveillance policy remains the most popular option after orchiectomy.
- 1 November 2011
- Vol. 17 (11) , 1007-10
[Stage I testis teratoma in adults: treatment options and recurrence factors].
To study the clinical outcomes of stage I testis teratoma, including pure teratoma, and to provide information on the treatment options for this disease. We retrospectively analyzed 27 cases of orchiectomy for stage I testis teratoma, excluding epidermoid cyst, and investigated its recurrence associated with treatment methods and clinicopathological factors. Four of the 27 cases relapsed, all in the orchiectomy group and confined to the retroperitoneal region, 3 with and the other 1 without risk factors, but with no death. No recurrence was found in those treated by orchiectomy followed by chemotherapy with bleomycin, etoposide and platinum (BEP). The total rate of recurrence was 15.8%. No severe side effects were observed in the 9 patients undergoing adjuvant BEP chemotherapy. Risk factors may increase the recurrence rate of stage I testis teratoma, while postoperative adjuvant chemotherapy can reduce it, including that of pure teratoma, though surveillance policy remains the most popular option after orchiectomy.
- Open Access
- 22 September 2011
- Published by Springer Nature in Molecular Biology Reports
- Vol. 39 (4) , 4429-4437
DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case–control studies
The association between polymorphism of DNA methyltransferases 3B and cancer risk has been widely studied recently, and no consensus conclusion is available up to now. We perform a comprehensive search using the databases of Medline, ISI Web of Knowledge and Embase. The odds ratio (OR) and its 95% confidence interval (95% CI) are used to investigate the strength of the association. A total of 24 case–control studies with 15,647 individuals are included in this meta-analysis. For −149C > T (17 studies, 5229 cases and 6910 controls), no evidence indicate that individuals carrying the variant genotypes (CC + CT), relative to those carrying the wild homozygote TT genotype, have an increased risk of cancer (OR = 1.03; 95% CI = 0.84–1.26; P = 0.76). Similarly, no cancer risk is found in the subgroup analyses. For −579G > T (11 studies, 3513 cases and 3714 controls), significantly decreased risks of cancer are observed, and the ORs (95% CI) are 0.70 (0.56–0.87) for GT versus TT, 0.70 (0.57–0.85) for GG + GT versus TT and 0.76 (0.63–0.93) for G-allele versus T-allele, respectively. Subgroup analyses stratified by ethnicity and types of cancer are also performed, and results indicated that −579G > C polymorphism is associated with risk of cancer in Asians [0.68 (0.53–0.87) for GT vs. TT] but not in Europeans [0.82 (0.63–1.07) for GT vs. TT]. We also observe that the −579G is associated with decreased risk of colorectal cancer [0.49(0.38–0.62) for GT vs. TT]. More studies with larger sample size were needed to provide more precise evidence.
- 22 September 2011
- Published by Springer Nature in Molecular Biology Reports
- Vol. 39 (4) , 4429-4437
Open AccessDNMT3B polymorphisms and cancer risk: a meta analysis of 24 case–control studies
The association between polymorphism of DNA methyltransferases 3B and cancer risk has been widely studied recently, and no consensus conclusion is available up to now. We perform a comprehensive search using the databases of Medline, ISI Web of Knowledge and Embase. The odds ratio (OR) and its 95% confidence interval (95% CI) are used to investigate the strength of the association. A total of 24 case–control studies with 15,647 individuals are included in this meta-analysis. For −149C > T (17 studies, 5229 cases and 6910 controls), no evidence indicate that individuals carrying the variant genotypes (CC + CT), relative to those carrying the wild homozygote TT genotype, have an increased risk of cancer (OR = 1.03; 95% CI = 0.84–1.26; P = 0.76). Similarly, no cancer risk is found in the subgroup analyses. For −579G > T (11 studies, 3513 cases and 3714 controls), significantly decreased risks of cancer are observed, and the ORs (95% CI) are 0.70 (0.56–0.87) for GT versus TT, 0.70 (0.57–0.85) for GG + GT versus TT and 0.76 (0.63–0.93) for G-allele versus T-allele, respectively. Subgroup analyses stratified by ethnicity and types of cancer are also performed, and results indicated that −579G > C polymorphism is associated with risk of cancer in Asians [0.68 (0.53–0.87) for GT vs. TT] but not in Europeans [0.82 (0.63–1.07) for GT vs. TT]. We also observe that the −579G is associated with decreased risk of colorectal cancer [0.49(0.38–0.62) for GT vs. TT]. More studies with larger sample size were needed to provide more precise evidence.